Skip to Main Content

Paper Details

Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial.
Ann Oncol
78
2021
Author NameAffiliation
Ramona F SwabyMerck & Co., Inc.
  • 1 - 1

Datasets

Release 1.2